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98.4%, Flow-CAST 92.1%) and allow the detection of the cul-
prit insect in patients with reactivity to both insects. The 
concordance between methods was good. There is no cor-
relation between severity of clinical reaction and cellular 
 assays.  Conclusion: CAST-ELISA and Flow-CAST are valuable 
additional diagnostic tools for establishing the true culprit 
insect in patients with unclear clinical history or sensitization 
to both insects.  Copyright © 2008 S. Karger AG, Basel 
 Introduction 
 Systemic hypersensitivity reactions to hymenoptera 
stings have been reported to occur in 0.8–5% of the gen-
eral population  [1–3] , the vast majority of these being im-
mediate-type, IgE-mediated reactions. They may be very 
severe and even life-threatening with 0.09–0.45 deaths 
per million within the general population  [4, 5] . The in-
sects most frequently involved are honey bee (HB) and 
yellow jacket (YJ) wasp.
 Standard diagnostic procedures include skin tests (ST, 
skin prick tests or preferably intradermal tests with pro-
gressive dilutions up to 1   g/ml of insect venom extracts) 
and determination of specific IgE (sIgE) in the serum 
against HB or YJ venom. Occasionally, venom-specific 
IgG response is added to the diagnostic armament. Nei-
ther the absolute amount of venom-specific IgE nor of 
IgG allows the prediction of the severity of a possible fu-
ture reaction to a sting  [6] . Sting challenge tests are con-
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 Abstract 
 Background: The current diagnostic procedures of anaphy-
lactic reactions to hymenoptera stings include intradermal 
tests, venom-specific IgE (sIgE) and possibly sting challenge 
tests. Sometimes, the culprit insect remains unidentified. 
The usefulness of the cellular assays CAST  -ELISA and Flow-
CAST  in the management of hymenoptera venom allergy 
was investigated.  Methods: 134 patients with systemic reac-
tions after a yellow jacket wasp and/or honey bee sting and 
44 healthy controls underwent skin tests, as well as determi-
nation of sIgE (CAP-FEIA), leukocyte sulfidoleukotriene re-
lease (CAST-ELISA) and basophil CD63 expression (Flow-
CAST) upon insect venom stimulation. The clinical diagnosis 
based on the history alone served as reference. Sensitivity, 
specificity, and positive and negative predictive value of all 
methods were compared. Concordance and correlations 
among methods were calculated.  Results: Sensitivity and 
specificity of all in vitro tests were consistently high. The 
combination of all tests (skin tests, sIgE, combined cellular 
assays) yielded a positive predictive value of 100% for both 
venoms, if all 3 were positive, and a negative predictive value 
of 100%, if at least 1 test was positive. Relative specificities 
were considerably higher for the cellular assays (honey bee: 
CAST 91.1%, Flow-CAST 85.7%; yellow jacket wasp: CAST 
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sidered the gold standard, although the negative predic-
tive value is low. Also, they pose the risk of life-threaten-
ing anaphylaxis and are therefore only performed in few 
specialized allergy units  [3] .
 Although these combined techniques allow an accu-
rate diagnosis in the majority of cases, a sizeable number 
of patients exists in whom, despite a convincing clinical 
history, ST and/or venom-specific IgE remain negative or 
ambiguous, not taking into account the cases with un-
clear clinical history.
 Golden et al.  [7] investigated 307 patients with a clear 
history of systemic immediate-type reaction after a hy-
menoptera sting. Ninety-nine patients (32%) had negative 
ST, of which 57% (56 patients) had negative sIgE and only 
7 patients high levels of sIgE. Anliker et al.  [8] found neg-
ative ST and negative or low-level sIgE in 24% of patients 
with convincing clinical history. Golden et al.  [7] showed 
that these patients are at risk of another systemic reaction 
if stung again, and also that ST and venom-specific IgE 
are frequently (up to 20%) discordant.
 In addition, the timing of diagnostic procedures in re-
lation to the anaphylactic event seems to be crucial. Based 
on 41 patients, Goldberg and Confino-Cohen  [9] showed 
that up to one quarter of the patients exhibited negative 
ST and sIgE within 1 week of the original systemic reac-
tion.
 Up to 50% of insect venom-allergic patients show dual 
sensitivity to HB and YJ venoms when analyzed by ST or 
sIgE  [10, 11] ; however, many of these double positivities 
do not seem to be clinically relevant  [10] .
 These difficulties, together with the risk and insecu-
rity of diagnostic sting challenges, require the develop-
ment and evaluation of additional diagnostic tech-
niques.
 In recent years, 2 new and promising in vitro test 
methods have been introduced: the sulfidoleukotriene 
(sLT) release by basophils, assessed by ELISA (CAST  -
ELISA) and the activation of the basophilic CD63 mark-
er as measured by flow cytometry (Flow-CAST  ). The 
latter test is also known as basophil activation test (BAT) 
or flow-cytometric allergen stimulation test (FAST).
 CAST-ELISA assesses the in vitro release of sLT from 
blood leukocytes of presumably allergic patients upon 
stimulation with various doses of the allergen. This tech-
nique has been shown to be a valuable diagnostic tool in 
certain inhalant, food, occupational and drug allergies 
 [12–14] .
 Flow-CAST investigates the allergen-induced in vitro 
activation of basophils as determined by the demonstra-
tion of the CD63 molecule on the basophil membrane. 
CD63 is normally expressed on the inside of vesicle mem-
branes. Under membrane-bound IgE cross-linking, the 
fusion of the vesicle to the plasma membrane allows the 
expression of CD63 on the external membrane and can 
then be detected by flow cytometry  [15, 16] . Several re-
ports proved its potential role in inhalant, food, latex and 
drug allergy  [17–19] .
 The main aim of this study was to compare the results 
of different in vivo  and in vitro methods with the clinical 
diagnosis obtained by comprehensive evaluation of the 
clinical history which served as the gold standard. Our 
study investigates the usefulness of CAST-ELISA and 
Flow-CAST in the diagnosis and management of hyme-
noptera venom allergy. Sensitivity, specificity, negative 
(NPV) and positive predictive value (PPV) of ST, sIgE, 
Flow-CAST and CAST-ELISA in comparison to the clin-
ical history were investigated in 134 patients with sys-
temic reactions after hymenoptera stings, not yet under 
specific immunotherapy (SIT). The relative specificities 
to the culprit insect as well as concordances and correla-
tions among methods are also shown.
 Material and Methods 
 Data from 200 consecutive patients with a suspected systemic 
reaction to hymenoptera stings who reported to the Allergy Unit 
of the University Hospital in Basel between December 1999 and 
May 2004 were collected. No restrictions were made as to age, sex, 
medications, other diseases or any other condition. Thirty-seven 
patients were excluded for reasons such as insufficient medical 
history (n = 22), unclear reaction (n = 11) or technical reasons
(n = 4) and a further 29 patients because they were currently under 
SIT. The remaining 134 patients (age range 7–74 years, mean 38.9 
 8 17.4 years; 82 males, 52 females) had reacted to stings of either 
HB (n = 55) or YJ (n = 67) or both (n = 12).
 According to the classification by Mueller  [20] , 11 had experi-
enced a grade I allergic reaction, 33 a grade II, 51 a grade III and 
39 a grade IV anaphylactic reaction. 
 Forty-four nonsensitized subjects served as volunteer controls 
(age range 18 and 60 years, mean 39.2  8 11.7 years; 12 males, 32 
females). Approval of the Ethics Committee of the University 
Hospital of Basel was obtained, as well as informed consent. 
 The patients underwent a routine allergologic evaluation con-
sisting of a detailed history of the event, intradermal ST, determi-
nation of sIgE against HB and YJ venom in the serum by CAP-
FEIA (UniCAP 100; Pharmacia, Uppsala, Sweden) and 2 insect 
venom-induced cellular activation assays (CAST-ELISA and 
Flow-CAST; Bühlmann Laboratories AG, Schoenenbuch, Swit-
zerland).
 Intradermal ST were performed on the volar side of the fore-
arm in a titrating fashion starting with the injection of 0.05 ml of 
HB and YJ venom solutions, each containing 0.0001   g/ml of ven-
om protein extract (ALK-Abelló, Horsholm, Denmark). Hista-
mine (0.1 mg/ml; Allergopharma, Reinbek, Germany) and albu-
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min diluents served as controls. In case of negativity of the first 
test, the test dose was increased 10-fold every 15 min until either 
a positive reaction occurred or the highest dose of 1   g/ml of both 
venoms was reached. A positive reaction was defined as a wheal 
larger than the negative control after 15 min  [21] . 
 Control subjects underwent a detailed interrogation regarding 
prior hymenoptera stings, medications and any other health con-
dition. Healthy volunteers without any prior anaphylactic reac-
tion to hymenoptera venom were enrolled. Skin prick tests were 
performed on the volar forearm with 3 concentrations of HB and 
YJ venom each (10, 100 and 300   g/ml; ALK-Abelló). Histamine 
(10 mg/ml; ALK-Abelló) and 0.9% NaCl served as controls. A test 
reaction was evaluated as positive if the wheal size was  1 3 mm 
after 15 min and a flare was present  [21] . CAST-ELISA, Flow-
CAST and sIgE were also determined.
 CAST-ELISA and Flow-CAST 
 CAST-ELISA and Flow-CAST were performed by the manu-
facturer (Bühlmann Laboratories AG) according to the standard 
protocols included in the commercially available test kits. Cells 
were stimulated with IL-3 and incubated for 40 min with several 
final concentrations of insect venom (2, 5, 10 and 20 ng/ml for 
CAST-ELISA; 5, 12.5 and 25 ng/ml for Flow-CAST; venom: ALK-
Abelló).
 Statistical Methods 
 Data of patients’ and control subjects’ age distribution, of 
CAST-ELISA (pg/ml sLT net release) and Flow-CAST (percentage 
of CD63+ basophils) are expressed as means  8 1 SD. Baseline 
characteristics of the cellular assays were all nonnormally distrib-
uted and were compared within and between control subjects and 
patients using the Mann-Whitney U test for independent and the 
Wilcoxon signed-rank test for related samples. The differences of 
the cellular  reactions to the stimulus (positive control, HB, YJ) 
within and between patient and control subgroups were analyzed 
using the independent t test for FLOW-CAST (normally distrib-
uted samples) and the median test for CAST-ELISA (nonnormal-
ly distributed samples). The concordance of all in vivo and in vitro 
tests was calculated using the   test for agreement. The correla-
tions between the different methods were analyzed using the 
Spearman rank correlation coefficient (rs). Possible correlations 
between the magnitude of the test responses to the allergens and 
the severity of clinical symptoms were determined using ANOVA 
on anaphylaxis grades (Kruskal-Wallis H test). The McNemar test 
was used to test the changes in reacting to the nonculprit insect 
venoms between the different test methods ( table 4 a and b). p  ^  
0.05 were considered significant.
 Results 
 sLT Production 
 The basal (spontaneous) mediator release (CAST-ELI-
SA) was compared with the sLT release upon stimulation 
with the stimulation control (anti-Fc  RI antibody, clone 
22E7  [22] ) as well as HB and YJ venom at the optimum 
allergen concentration for both patients and control sub-
jects ( fig. 1 a). The stimulation capacity of leukocytes var-
ied considerably among individuals. Between 15 and 30% 
(stimulated by allergens) and up to 70% (stimulated by 
stimulation control) of so-called high-sLT releasers ex-
hibited sLT levels above the upper detection limit of 3,200 
pg/ml. These sLT values were uniformly set at 3,200 pg/
ml and might therefore bias high sLT results (see correla-
tion data below). 
 CD63 Upregulation 
 Basal (spontaneous) CD63 upregulation (Flow-CAST) 
was compared with CD63 expression upon stimulation 
with the stimulation control and HB and YJ venom at the 
optimum allergen concentration, for both patients and 
control subjects ( fig. 1 b). Two control subjects with large 
local but no systemic reactions showed elevated CD63 ex-
pression of 29 and 62%, when tested with HB venom. Af-
ter exclusion of these 2 controls, the mean CD63 expres-
sion (4.3  8 2.3) did not differ from those of basal CD63 
expression levels.
 CD63 expression induced by 25 ng/ml of HB venom 
was significantly lower than with either stimulation con-
trol (p = 0.0061) or YJ venom (p = 0.0255). The CD63 ex-
pression of control subjects upon venom stimulation was 
in the same range as the spontaneous CD63 levels of con-
trols and patients.
 Diagnostic Potential of the Cellular Tests 
 For the determination of the diagnostic potential of 
the cellular assays, the definition of the cutoff chosen for 
positivity is important, since both venom extracts may 
contain obligate nonspecific basophil stimulators that 
might cause false-positive reactions  [23] . Therefore, HB 
and YJ allergen concentrations for stimulation must not 
be too high and the cutoff should be based on the evalu-
ation of normal, nonsymptomatic controls. For CAST-
ELISA, 67 HB-allergic, 78 YJ-allergic patients and 44 
healthy volunteers were enrolled. The optimal threshold 
(cutoff point) to differentiate between negative and posi-
tive HB and YJ results was determined at 4 different al-
lergen concentrations by plotting the true-positive results 
(in reference to the clinical history) against the false-pos-
itive results by ROC curves (data not shown). For both 
venoms, the curves followed the left-hand and then the 
top border, indicating high accuracy. The high sensitivity 
and specificity for HB and YJ are listed in  table 1 . For 
CAST-ELISA the values selected fitted a net sLT release 
of 261 pg/ml for YJ and 266 pg/ml for HB at the best-
matching allergen concentration of 10 ng/ml each. The 
same procedure was applied for Flow-CAST by compar-
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ing 19 HB and 45 YJ patients with the same controls (n = 
39) using 3 different allergen concentrations. The select-
ed values for sensitivity and specificity correspond to a 
CD63 expression on  6 10% of basophils for both insect 
venoms at the best-matching allergen concentration of 25 
ng/ml each.
 The results of the ST, sIgE and cellular allergy assays 
were then correlated with the definitive clinical diagno-
sis. The number of individuals analyzed differed among 
the various test methods. One sIgE result of a control 
subject, some ST of the patients and 2 of the controls 
were not available. As the Flow-CAST   method was in-
troduced only in February 2002, the number of patients 
evaluated with this method was substantially lower. 
Separate results are shown for HB ( table 1 a) and YJ ( ta-
ble 1 b). Twenty patients exhibiting an anaphylactic reac-
tion to both insects were enrolled in both the HB and YJ 
evaluation. 
 Predictive Values 
 The combination of the cellular assays (at least 1 posi-
tive result in a patient) yielded sensitivities (HB: 94.7%; 
YJ: 95.6%) which were as high as the ones for ST. The 
combination of both cellular assays (both results positive 
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 Fig. 1. Basal and induced (stimulation con-
trol, HB and YJ venom) sLT releases ( a ) 
and CD63 expression ( b ) for control sub-
jects and patients (means  8 1 SD). Medi-
ans (horizontal lines) are shown only for 
stimulated samples. 
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in a control subject) yielded specificities (HB: 97.4%; YJ: 
100%) which were higher than for ST. 
 Of special importance for clinical situations is the fact 
that the combination of all 3 methodologies, ST, CAP-
FEIA and combined cellular assays, achieved a sensitiv-
ity of 100% (NPV = 1) for both HB and YJ. None of the 
controls had positive results in all 3 methodologies (spec-
ificity 100%, PPV = 1;  table 1 ).
 Concordance 
 All 4 methods showed K (  test) values between 0.66 
and 0.84 to each other, with a tendency of somewhat 
higher values for HB ( table 2 ). In HB, the cellular assays 
are advantageous to sIgE (K = 0.77). Overall, the agree-
ment to the clinical diagnosis was very stable with K val-
ues above 0.81 (except 0.77 in HB CAP-FEIA) for all in 
vitro tests, indicating an acceptable performance of all 
methods in the diagnosis of hymenoptera venom al-
lergy.
 Correlations 
 The absolute correlations as calculated by the Spear-
man rank correlation coefficient (rs) between the differ-
ent test methods were only weak or not existent ( table 3 ). 
This phenomenon might be due to the fact that approxi-
mately 30% of the CAST-ELISA results were above the 
upper detection limit of 3,200 pg/ml sLT release. All data 
above this upper limit were considered as 3,200 pg/ml net 
release and did, therefore, not reflect the effective magni-
tude of stimulation by the venom allergens, possibly lead-
ing to negatively biased CAST-ELISA correlations. 
 Relative Specificities 
 To elucidate the relative specificity for identifying the 
true culprit insect as defined by the clinical history, the 
number of false-positive results for YJ in clinically HB-
allergic patients and vice versa ( table 4 a and b) was deter-
mined. This showed a much higher relative specificity of 
the cellular in vitro allergy assays (HB: CAST-ELISA 
91.1%, Flow-CAST: 85.7%; YJ: CAST-ELISA 98.4%, Flow-
Table 1. Sensitivity, specificity, PPV and NPV in relation to the clinical diagnosis for HB- and YJ-allergic patients and for the combi-
nation of all testing modalities (ST, sIgE, combined cellular assays)
a HB-allergic patients
CAST Flow-CAST CAST and Flow-
CAST combined 
CAP-FEIA ST 1 (of 3) methods 
positive
All 3 methods 
positive
Patients/controls, n 67/44 19/39 19/39 67/43 63/42 67/41 65/44
Sensitivity, %
95% CI, %
94.0
85.4–98.3
89.5
66.9–98.7
94.7
74.0–99.9
92.5 93.7 100 86.2
Specificity, %
95%, CI %
93.2
81.3–98.6
94.9
82.7–99.4
97.4
86.5–99.9
83.7 97.6 75.6 100
NPV 0.911 0.895 0.972 0.878 0.911 1 0.830
PPV 0.955 0.949 0.941 0.899 0.983 0.870 1
b YJ-allergic patients
CAST Flow-CAST CAST and Flow-
CAST combined 
CAP-FEIA ST 1 (of 3) methods 
positive
All 3 methods 
positive
Patients/controls, n 78/44 45/39 45/39 79/43 77/42 79/44 77/44
Sensitivity, %
95% CI, %
88.5
79.2–94.6
86.7
73.2–94.9
95.6
84.9–99.5
92.4 97.4 100 88.3
Specificity, %
95% CI, %
95.5
84.5–99.4
97.4
86.5–99.9
100
91.0–100
93.0 92.9 86.4 100
NPV 0.824 0.864 0.947 0.870 0.951 1 0.830
PPV 0.972 0.975 1 0.961 0.962 0.929 1
Positivity was declared if (1) 1 of the tests was positive and (2) if all tests were positive.
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CAST 92.1%) than of any of the other tests which reached 
statistical significance. The reciprocal value of the rela-
tive specificity corresponds to the value of nonrelevant 
sensitization which is much lower in the cellular assays 
than in the CAP-FEIA and ST. The high specificity of the 
cellular assays is only partly offset by a small loss of sen-
sitivity. In case of HB-positive patients, the sensitivity of 
CAST-ELISA remains well at the same level as that of 
CAP-FEIA and ST. In YJ, sensitivity of the cellular assays 
remains still high, although lower than for CAP-FEIA 
and ST. The small loss of sensitivity is, however, discrete 
if compared to the considerable gain in relative specific-
ity for the culprit insect. Due to the fact that Flow-CAST 
has only been introduced in 2002, not all patients were 
tested with all methods. The high relative specificity for 
identifying the culprit insect is, however, not affected by 
this. The relative specificities and sensitivities were also 
calculated for the smaller collective of patients in whom 
all 4 tests were available (numbers in parentheses in  ta-
ble 4 a). They do not differ greatly from the numbers of 
the whole study group. 
 To demonstrate that the cellular assays show negative 
results for the nonculprit insect in those patients that ex-
hibit strongly positive values for CAP-FEIA and ST, the 
individual data of the patients with at least 1 positive test 
for the nonculprit insect are given in  table 4 b.
 Severity of Anaphylaxis 
 Finally, we tested the hypothesis that the cellular al-
lergy tests may be suitable to predict the severity of an 
anaphylactic reaction due to an insect sting. A possible 
correlation between the anaphylaxis grade according to 
Mueller  [20] and the magnitude of sLT release, CD63 up-
regulation and sIgE levels in response to the hymenoptera 
venoms was calculated using ANOVA on ranks ( table 5 ). 
We found no significant differences, neither in the degree 
of sLT release and basophil activation nor in the sIgE lev-
els between the groups of patients with clinical grades 
I–IV. In general, in vitro assays and ST seemed to better 
reflect the clinical diagnosis in HB than in YJ.
 Discussion 
 This study represents a large collective of hymenop-
tera-allergic patients investigated with cellular activation 
tests. It analyzes in detail the usefulness of the 2 cellular 
allergy tests, CAST-ELISA and Flow-CAST, for the diag-
nosis of hymenoptera venom allergy in comparison to 
established testing procedures. 
 The recent literature concerning CAST-ELISA and 
particularly Flow-CAST suffers from minor or major dif-
ferences in performing the tests ( table 6 ) and from the 
HB/YJ CAST Flow-CAST CAP-FEIA ST Clinical diagnosis
CAST 0.81 0.71 0.82 0.87
Flow-CAST 0.71 0.73 0.70 0.84
CAP-FEIA 0.69 0.66 0.72 0.77
ST 0.71 0.76 0.82 0.90
Clinical diagnosis 0.81 0.83 0.84 0.91
K values: >0.6 = good agreement; >0.8 = very good agreement; 1 = absolute agree-
ment.
Table 2. Concordance (K values) between 
the different test methods and their 
agreement with the clinical diagnosis
calculated using the  test for agreement
HB/YJ CAST Flow-CAST CAP-FEIA ST
CAST 0.08 (0.7345) 0.03 (0.7964) 0.13 (0.3173)
Flow-CAST 0.47 (0.0011) 0.25 (0.1328) 0.25 (0.1259)
CAP-FEIA –0.01 (0.9256) 0.03 (0.8120) 0.41 (0.0002)
ST 0.07 (0.5605) 0.28 (0.0268) 0.42 (<0.0001)
Figures in parentheses are p values.
Table 3. Correlations between the 
different test methods determined
by the Spearman rank correlation 
coefficient (rs)
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Table 4. Relative specificities of the various test methods for detecting the culprit insect and patients exhibiting positivity to the non-
culprit insect
a Relative specificities
CAST Flow-CAST CAP-FEIA ST
HB positive, but YJ negative
YJ negative/YJ positive, n 41/4 (12/0) 12/2 (10/2) 26/18 (8/4) 22/14 (7/5)
Relative specificity for HB, % 91.1 (100) 85.7 (83.3) 59.1a (66.6) 61.1a (58.3)
Sensitivity for HB, % 91.1 (83.3) 85.7 (83.3) 93.2 (91.7) 91.7 (83.3)
YJ positive, but HB negative 
HB negative/HB positive, n 60/1 (35/1) 35/3 (33/3) 30/30 (15/21) 36/21 (28/8)
Relative specificity for YJ, % 98.4 (97.2) 92.1 (91.7) 50.0b, d (41.6)b, e 63.2b (77.8)
Sensitivity for YJ, % 88.5 (88.9) 86.8 (88.9) 95.0 (91.6) 98.2c (100)
b Patients exhibiting positivity to the nonculprit insect with at least 1 method
Patient Test result for HB Test result for YJ
ST positive
g/ml
CAST Flow-
CAST
CAP-FEIA
kU/l
ST positive
g/ml
CAST Flow-
CAST
CAP-FEIA 
kU/l
HB 9 neg. 953 71 0.52 neg. 49 62 0.34
HB 80 0.1 611 20 3.22 0.1 7 2 0.34
HB 87 0.001 1,660 17 2.35 0.01 209 5 0.56
HB 101 0.01 579 79 50.7 0.01 109 22 0.34
HB 102 0.1 1,901 33 59.1 neg. 49 4 1.8
HB 117 0.01 447 36 20.1 0.1 106 5 2.5
HB 149 0.001 296 46 14.7 1 45 1 0.61
YJ 1 0.1 98 4 1.02 0.0001 3,132 5 16
YJ 19 neg. 10 1 4.95 1 2,044 3 3.35
YJ 24 neg. 203 5 3.04 0.1 3,200 60 6.73
YJ 86 neg. 298 57 9.94 0.1 3,200 78 4.9
YJ 88 neg. 53 0 1.16 0.001 2,239 85 50.9
YJ 89 1 93 6 1.98 0.0001 946 74 15.4
YJ 94 neg. 111 2 1 0.001 2,815 63 1.91
YJ 100 0.1 39 8 6.48 0.1 11 4 6.67
YJ 115 neg. 64 16 0.34 0.01 2,417 89 0.81
YJ 121 neg. 92 6 8.76 0.0001 2,970 85 100
YJ 127 neg. 139 4 0.52 0.01 3,180 52 1.08
YJ 129 0.01 123 2 10.7 0.01 1,489 12 8.35
YJ 132 0.1 146 3 0.34 0.01 302 3 3.61
YJ 133 neg. 62 6 0.6 1 404 28 100
YJ 137 neg. 199 5 0.4 1 292 25 0.8
YJ 138 neg. 172 12 0.35 0.01 3,200 73 4.88
YJ 140 neg. 119 6 4.99 0.001 1,084 49 100
YJ 146 neg. 211 3 6.03 0.001 171 17 15.1
YJ 148 0.01 51 2 1.97 0.01 49 43 0.39
YJ 151 1 48 6 0.36 0.01 1,223 44 0.34
YJ 152 neg. 159 1 1.03 0.001 102 49 16.8
YJ 153 neg. 103 4 4.92 0.001 528 26 13.3
YJ 154 1 80 9 0.84 0.01 1,702 48 1.8
The numbers of correctly negative and falsely positive results are shown. The figures in parentheses are the results of patients in 
whom all 4 test results were available. The individual patients’ results from table 4a with positive results for the nonculprit insect (in 
bold letters) are represented in table 4b. Neg. = Negative. a p < 0.01, b p < 0.0001 for CAST-ELISA; c p < 0.01, d p < 0.05, e p < 0.0001 for 
Flow-CAST. Numbers of HB-positive/YJ-negative cases analyzed by Flow-CAST were too low to reach statistical significance.
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small numbers of patients and/or controls investigated. 
This makes comparison between studies and transfer-
ability of the results difficult. This study uses well-estab-
lished, commercially available and highly standardized 
test procedures so that laboratory-related variations in 
performance can be excluded. This should grant a high 
interlaboratory reproducibility and reduce the diversifi-
cation of methods to be used in the future. 
 A number of controlled studies demonstrated the high 
sensitivity of CAST-ELISA in hymenoptera-allergic pa-
tients between 68 and 100%  [4, 8, 24–26] . Studies by Maly 
et al.  [27, 28] on 23 HB- or YJ-allergic patients showed the 
sensitivity of CAST-ELISA to be higher in patients with 
positive ST (88%) than in patients with negative ST (66%). 
Also, CAST-ELISA was positive in 87% of the patients 
with clinical history but negative ST and sIgE. In all cas-
es, the reported sensitivity of CAST-ELISA was superior 
to that of ST (76–85%) and sIgE (70–87%). The specific-
ity of CAST-ELISA in these studies  [4, 25–28] varied be-
tween 67 and 100%; however, control groups were not 
uniformly selected and tested among these studies  [15–
19] . For the interpretation of the above results it has also 
to be taken into consideration that ST were not uniform-
ly performed and are only barely standardized.
 The overall sensitivity of the various flow-cytometric 
methods in 10 controlled HB and/or YJ studies  [4, 29–37] 
varied significantly, as well as the methods used and the 
populations tested ( table 6 ). In a recent publication on 57 
patients with systemic reactions to hymenoptera, Eber-
lein-König et al.  [34] admonish the fact that data on BAT 
for HB-allergic and HB/YJ-allergic patients investigated 
with the exact same method are not available.
 SIT is a very effective therapeutic means in hymenop-
tera venom-allergic patients. Due to possible risks of ana-
phylactic reactions during therapy  [38] and a usual dura-
tion of 3–5 years, the indication for SIT requires an un-
equivocal diagnosis which is sometimes difficult with the 
standard diagnostic means  [10, 11] . Reliable, easily acces-
sible parameters are still to be found to determine the ef-
ficacy of immunotherapy. Kosnik et al.  [35] correlated the 
likelihood of side effects under SIT with the degree of ba-
sophil sensitivity to allergen-specific in vitro stimulation 
in 34 patients. Eberlein-König et al.  [39] , however, could 
not reproduce these results in their patient collective of 
57 patients, but that may be attributable to variations in 
methodology.
 One of the aims of this study was the revised determi-
nation of clinical cutoff values for positivity of CAST-
ELISA and Flow-CAST on a large, well-defined patient 
collective. Sensitivities and specificities of HB and YJ 
CAST-ELISA were plotted against each other, resulting in 
ROC curves nearing infinity. Cutoff values were fixed in 
the bend of the curves at points compromising high sen-
sitivity with reliable specificity ( table 1 a and b). These 
new cutoff values are now set at 270 pg/ml of sLT release 
for both HB and YJ, using 10 ng/ml of insect venom for 
stimulation. The same procedure was applied for Flow-
CAST, yielding a cutoff value of 10% CD63 expression for 
both HB and YJ, using 25 ng/ml of insect venom for stim-
ulation.
 In general, sensitivities and specificities of the cellular 
allergy assays in our study were somewhat better than 
sIgE as measured by CAP-FEIA in hymenoptera venom 
diagnosis, and only slightly surpassed by the ST. This is 
in contrast to most of the current literature. Sensitivity is 
said to be higher for CAST-ELISA than for venom-spe-
cific IgE  [26–28] or both sIgE and ST  [4, 8] and higher for 
BAT than sIgE  [32] or both sIgE and ST  [4, 30] . In some 
of these studies, the differences between the diagnostic 
means were considerable. For our study, it is striking that 
although small differences can be observed between the 
cellular assays, ST and CAP-FEIA, the results are very 
consistent between the various tests due to vigorous pa-
tient selection. The high specificity may be influenced by 
using skin prick tests in the control group which might 
be less sensitive than the intradermal test leading to a low 
false-positive fraction in the control volunteers. 
 The combined use of CAST-ELISA and Flow-CAST 
further increases the sensitivity, however with a loss of 
specificity, when 1 of the 2 assays is positive. All patients 
who were negative in ST and/or sIgE show a positive re-
sult in at least 1 of the cellular assays for both HB and YJ 
venom. Thus, the combination of all 3 methodologies 
achieves a sensitivity of 100% or an NPV of 1 ( table 1 a and 
b). Conversely, none of the 44 control subjects was found 
Table 5. Correlation between the severity of the anaphylactic re-
action of each patient and individual test results
CAST Flow-CAST CAP-FEIA ST
HB 0.6466 0.0999 0.5984 0.0083
YJ 0.9850 0.7422 0.3526 0.5836
The severity of the anaphylactic reaction of each patient was 
correlated with each individual test result of the different meth-
ods using ANOVA on ranks (Kruskal-Wallis H test).
p < 0.05 indicates that the corresponding method may signif-
icantly predict the severity of a patient’s anaphylactic reaction.
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to be positive with all 3 methods, neither with HB nor 
with YJ venom. Thus, the diagnostic work-up conse-
quently using all 3 methodological approaches as pre-
sented in this study not only leads to 100% sensitivity, but 
also to 100% specificity or a PPV of 1. Overall, CAST-
ELISA and Flow-CAST can be considered valuable addi-
tional therapeutic options in determining the culprit in-
sect, especially for those patients with contradictory clin-
ical and laboratory findings. 
 The total agreement of the different methods with the 
clinical diagnosis is consistently high ( table 2 ; K values 
0.81–0.91) except for HB in CAP-FEIA (K = 0.77). Not 
surprisingly, the concordance between the different 
methods is also high with K values between 0.69 and 0.82. 
However, the correlation of absolute results obtained by 
the different in vivo and in vitro methods is weak or not 
existent ( table 3 ). We could not demonstrate a positive 
correlation of the absolute value of either sLT release or 
CD63 expression with the severity of clinical symptoms 
to the insect sting ( table 5 ), as previously reported  [31] . 
Interestingly, we observed a weak correlation between 
the severity of symptoms to HB stings and the individual 
reactions to intradermal ST (p = 0.0083), but not in the 
case of YJ stings. The relatively weak or nonexistent cor-
Table 6. Study details and test conditions published in the recent literature
Ref. Specimen IL-3 
(2 ng/
ml)
Cell 
priming
at 37 °C
min
Incubation 
with aller-
gen at 
37 °C, min
Range of allergen 
concentrations 
tested, ng/ml
Basophil 
selection 
marker
Basophil 
activation 
marker
Healthy
con-
trols, 
n
Venom-
allergic 
subjects
n
Sensi-
tivity, %
Speci-
ficity, %
Optimum 
allergen 
concentra-
tion,  ng/ml
41 heparinized 
blood
no no 15 1,000 anti-
CD203c
anti-
CD203c
9 47 85–91 100 1,000
30 heparinized 
blood
no no 15 10–10,000 anti-IgE anti-
CD203c
13 22 83–94 85–100 1,000
36 heparinized 
blood
no 10 20 10–1,000 anti-IgE? anti-
CD203c
18 43 97 89 100–1,000
29 heparinized 
blood
no no 40 10–500 anti-IgE+/
anti-CD45+
anti-
CD63
8 26 77 88–100 500
32 heparinized 
blood
yes 10 20 0.5–50,000 anti-IgE anti-
CD63
20 50 92 80 500–5,000
33 heparinized 
blood
yes 10 20 4–4,000 anti-IgE anti-
CD63
12 20 100 100 400–4,000
34 heparinized 
blood
yes 10 20 10–1,000 anti-IgE anti-
CD63
10 18 97–100 100 1,000
36 heparinized 
blood
yes 10 20 10–1,000 anti-IgE anti-
CD63
18 43 89 100 100–1,000
37 heparinized 
blood
yes no 20 5–5,000 anti-IgE anti-
CD63
14 80 84 100 5,000
35 heparinized 
blood
yes no 15 100–1,000 anti-
CD123+/
anti-
HLA-DR–
anti-
CD63
10 34 100 70–100 1,000
31 PBMS 
(citrated 
blood)
no no 30 0.1–10,000 anti-
CD123+/
anti-
HLA-DR–
anti-
CD63
30 23 85–91 83–90 100–1,000
4 buffy coat 
(EDTA blood)
yes 15 45 20–500 anti-IgE anti-
CD63
12 12 100 100 20–500
This 
study
plasma 
leukocytes 
(EDTA blood)
yes no 40 5–25 anti-IgE anti-
CD63
39 100 89–91 95–97 25
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relations among the 3 methods on the one hand and
between laboratory tests including ST and clinical
symptoms on the other hand, suggest that different
mechanisms are involved in anaphylaxis, probably also 
including non-IgE-dependent mechanisms. 
 In up to 50% of patients who have been stung and who 
systemically reacted to one insect, the currently applied 
diagnostic methods show positivity for both HB and YJ 
 [10, 11] . Hemmer et al.  [10] showed that this double posi-
tivity on the IgE level is largely due to cross-reactive car-
bohydrate determinants with low clinical relevance, thus 
suggesting a probably negligible in vitro phenomenon. A 
clear differentiation between true double sensitization 
and clinically probably irrelevant double reactivity, espe-
cially with respect to a possible desensitization therapy, is 
mandatory – even more so if the culprit insect has not 
been recognized by the patient. The relative specificity of 
the methods for the culprit insect is shown in  table 4 a. 
Both CAST-ELISA and Flow-CAST exhibit a much high-
er relative specificity in this respect than any other meth-
od. The reciprocal value of the relative specificities in  ta-
ble 4 a represents the percentage of nonrelevant sensitiza-
tion in patients with double positivity in the other tests. 
This could be explained by the fact that cross-linking IgE 
and cross-reactive carbohydrate determinants do not 
play a role in the cellular assays which, therefore, are more 
likely to detect true, relevant sensitizations than CAP-
FEIA. This is probably the most relevant additional in-
formation to be gained by the cellular assays in the diag-
nosis of hymenoptera venom allergy. Eberlein-König et 
al.  [40] and Kosnik et al.  [35] demonstrated the same 
problem in 14 patients with inconsistent results between 
clinical history, ST and CAP-FEIA. They state that the 
additional performance of cellular tests may be helpful in 
difficult cases where history, ST and determination of 
sIgE do not allow a clear decision regarding the relevant 
insect species for immunotherapy. Binder et al.  [41] have 
also pointed out that there are clinically nonrelevant dou-
ble reactions as measured by sIgE which can be resolved 
by the use of BAT in combination with single purified or 
recombinant protein determinants originating from bee 
and wasp venoms.
 The cellular assays measuring de novo formed media-
tors are probably superior to the histamine release test 
that has sometimes been used in experimental settings  [4, 
27–29, 40] , although it never developed into a widely used 
routine diagnostic procedure due to the fact that hista-
mine release can also be triggered by nonspecific baso-
phil activators that are present in HB and YJ venom ex-
tracts  [42] . Maly et al.  [27, 28] even demonstrated a dis-
sociation of histamine release and sLT formation. Others, 
however, report a good correlation between the 2 tech-
niques  [4, 29–30] .
 In summary, the diagnosis of hymenoptera venom al-
lergy should not be made upon the result of a single in 
vitro or in vivo test alone, but several diagnostic methods 
should be taken into consideration. CAST-ELISA and 
Flow-CAST   are valuable diagnostic tools with special im-
portance in establishing the culprit insect in patients 
with unclear clinical history and possibly nonrelevant 
double reactivity in ST and/or CAP-FEIA (sIgE).
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